nach oben

DGNeurologie

Erschienen in:

20.02.2020 | Krankheiten des peripheren Nervensystems | CME Zertifizierte Fortbildung

Diagnostik immunvermittelter Polyneuropathien

verfasst von: Dr. med. N. B. Grether, Dr. med. G. Wunderlich, Prof. Dr. med. H. C. Lehmann

Erschienen in: DGNeurologie | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Immunvermittelte Polyneuropathien stellen innerhalb der Gruppe der Polyneuropathien eine häufige und aufgrund der vielfältigen therapeutischen Möglichkeiten äußerst relevante Differenzialdiagnose dar. Dennoch wird die Diagnose insbesondere chronisch verlaufender immunvermittelter Polyneuropathien häufig erst mit zeitlicher Verzögerung gestellt. Ein Grund hierfür ist das Fehlen sensitiver diagnostischer Biomarker. Oft ist es daher erst die Konstellation aus klinischen Symptomen, zeitlichem Verlauf und charakteristischen Befunden in der Zusatzdiagnostik, die die Diagnose erlaubt. Im folgenden Beitrag soll eine Übersicht über die Diagnostik immunvermittelter Polyneuropathien geben werden.

Hanewinckel R et al (2016) Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 87(18):1892–1898PubMed

Visser NA et al (2015) Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 84(3):259–264PubMed

Lehmann HC et al (2007) Incidence of Guillain-Barre syndrome in Germany. J Peripher Nerv Syst 12(4):285PubMed

Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barre syndrome. Lancet 388:717–727PubMed

Esposito S, Longo MR (2017) Guillain-Barre syndrome. Autoimmun Rev 16(1):96–101PubMed

Yoshikawa H (2015) Epidemiology of Guillain-Barre syndrome. Brain Nerve 67(11):1305–1311PubMed

Overell JR, Willison HJ (2005) Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol 18(5):562–566PubMed

Ruts L et al (2010) Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 74(21):1680–1686PubMed

Lehmann HC (2014) Chronisch inflammatorische demyelinisierende Polyneuropathie: Aktuelle Entwicklungen bei Diagnose und Therapie. Nervenheilkunde 7–8(33):535–539

10.

Mahdi-Rogers M, Hughes RA (2014) Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 21(1):28–33PubMed

11.

Katz JS et al (2000) Distal acquired demyelinating symmetric neuropathy. Neurology 54(3):615–620PubMed

12.

Viala K et al (2004) Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 127(9):2010–2017PubMed

13.

Lawson VH, Arnold WD (2014) Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr Dis Treat 10:567–576PubMed

14.

Rison RA, Beydoun SR (2016) Paraproteinemic neuropathy: a practical review. BMC Neurol 16:13PubMed

15.

Isobe T, Osserman EF (1971) Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann N Y Acad Sci 190:507–518PubMed

16.

Johansen P, Leegaard OF (1985) Peripheral neuropathy and paraproteinemia: an immunohistochemical and serologic study. Clin Neuropathol 4(3):99–104PubMed

17.

Collins MP, Hadden RD (2017) The nonsystemic vasculitic neuropathies. Nat Rev Neurol 13(5):302–316PubMed

18.

Lehmann HC, Burke D, Kuwabara S (2019) Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 90(9):981–987PubMed

19.

Potulska-Chromik A et al (2016) Are electrophysiological criteria useful in distinguishing childhood demyelinating neuropathies? J Peripher Nerv Syst 21(1):22–26PubMed

20.

Lozeron P et al (2018) Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 91(2):e143–e152PubMed

21.

Kaplan A, Brannagan TH (2017) Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 55(4):476–482PubMed

22.

Lichtenstein T et al (2018) MRI biomarkers of proximal nerve injury in CIDP. Ann Clin Transl Neurol 5(1):19–28PubMed

23.

Carroll CG, Campbell WW (2009) Multiple cranial neuropathies. Semin Neurol 29(1):53–65PubMed

24.

Ahlskog MC et al (2012) IgM-monoclonal gammopathy neuropathy and tremor: a first epidemiologic case control study. Parkinsonism Relat Disord 18(6):748–752PubMed

25.

Hadden RD et al (2006) European federation of neurological societies/peripheral nerve society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European federation of neurological societies and the peripheral nerve society. Eur J Neurol 13(8):809–818PubMed

26.

Nobile-Orazio E, Gallia F (2013) Multifocal motor neuropathy: current therapies and novel strategies. Drugs 73(5):397–406PubMed

27.

Joint Task Force of the EFNS and the PNS (2010) European federation of neurological societies/peripheral nerve society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European federation of neurological societies and the peripheral nerve society—first revision. J Peripher Nerv Syst 15(4):295–301

28.

Collins MP, Periquet MI (2008) Isolated vasculitis of the peripheral nervous system. Clin Exp Rheumatol 26(3):S118–30PubMed

29.

Uceyler N et al (2015) Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. J Neurol 262(9):2092–2100PubMed

30.

Chaudhry HM, Mauermann ML, Rajkumar SV (2017) Monoclonal gammopathy associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc 92(5):838–850PubMed

31.

Bril V et al (2010) Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 42(4):492–497PubMed

32.

Heuß D (2019) Diagnostik bei Polyneuropathien, S1-Leitlinie. In: Deutsche Gesellschaft für Neurologie (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie

33.

Singleton JR, Smith AG, Bromberg MB (2001) Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 24(9):1225–1228PubMed

34.

Watson JC, Dyck PJ (2015) Peripheral neuropathy: a practical approach to diagnosis and symptom management. Mayo Clin Proc 90(7):940–951PubMed

35.

England JD et al (2009) Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American academy of neurology, American association of neuromuscular and electrodiagnostic medicine, and American academy of physical medicine and rehabilitation. Neurology 72(2):185–192PubMed

36.

Delmont E et al (2017) Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain 140(7):1851–1858PubMed

37.

Doppler K et al (2018) Neurofascin-155 IgM autoantibodies in patients with inflammatory neuropathies. J Neurol Neurosurg Psychiatry 89(11):1145–1151PubMed

38.

Querol L et al (2014) Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82(10):879–886PubMed

39.

Ng JK et al (2012) Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79(23):2241–2248PubMed

40.

Miura Y et al (2015) Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 138(6):1484–1491PubMed

41.

Querol L et al (2013) Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 73(3):370–380PubMed

42.

Collins MP et al (2010) Peripheral nerve society guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 15(3):176–184PubMed

43.

Ruth A et al (2005) Diagnostic and therapeutic value due to suspected diagnosis, long-term complications, and indication for sural nerve biopsy. Clin Neurol Neurosurg 107(3):214–217PubMed

44.

Gabriel C et al (2000) Prospective study of the usefulness of sural nerve biopsy. J Neurol Neurosurg Psychiatry 69(4):442–446PubMed

45.

Grimm A et al (2016) Ultrasound pattern sum score, homogeneity score and regional nerve enlargement index for differentiation of demyelinating inflammatory and hereditary neuropathies. Clin Neurophysiol 127(7):2618–2624PubMed

46.

Telleman JA et al (2018) Nerve ultrasound in polyneuropathies. Muscle Nerve 57(5):716–728PubMed

47.

Grimm A et al (2019) Differentiation between Guillain-Barré syndrome and acute-onset chronic inflammatory demyelinating polyradiculoneuritis—a prospective follow-up study using ultrasound and neurophysiological measurements. Neurotherapeutics 16(3):838–847PubMed

48.

Razali SNO et al (2016) Serial peripheral nerve ultrasound in Guillain-Barré syndrome. Clin Neurophysiol 127(2):1652–1656PubMed

49.

Goedee HS et al (2017) Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology 88(2):143–151PubMed

50.

Kerasnoudis A et al (2014) Multifocal motor neuropathy: correlation of nerve ultrasound, electrophysiological, and clinical findings. J Peripher Nerv Syst 19(2):165–174PubMed

51.

Grimm A et al (2014) Ultrasound of the peripheral nerves in systemic vasculitic neuropathies. J Neurol Sci 347(1–2):44–49PubMed

52.

Üçeyler N et al (2016) High-resolution ultrasonography of the superficial peroneal motor and sural sensory nerves may be a non-invasive approach to the diagnosis of vasculitic neuropathy. Front Neurol 7:48PubMed

53.

Bril V et al (2016) The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications 30(7):1401–1407PubMed

Titel: Diagnostik immunvermittelter Polyneuropathien
verfasst von: Dr. med. N. B. Grether
Dr. med. G. Wunderlich
Prof. Dr. med. H. C. Lehmann
Publikationsdatum: 20.02.2020
Verlag: Springer Medizin
Schlagwörter: Krankheiten des peripheren Nervensystems
Polyneuropathie
Polyneuritis und Polyneuroradikulitis Typ Guillain-Barré
Erschienen in: DGNeurologie / Ausgabe 2/2020
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI: https://doi.org/10.1007/s42451-020-00156-y

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Klinische Versorgung von Patienten mit multipler Sklerose in Deutschland

Magazin

Fahreignung: Ärztliche Pflichten und Beurteilungsalgorithmen

Beiläufiger Nachweis entlarvt Ursache rezidivierender Schlaganfälle

Internationale „Brain Health Initiative“ und Multiple Sklerose

Mitteilungen der Deutschen Gesellschaft für Neurologie